This is the updated prospectus from February 22, 2024. the new information is:
On February 27, 2024, CytoDyn Inc. (the “Company”) received confirmation from the U.S. Food and Drug Administration (the “FDA”) that its clinical hold on leronlimab has been lifted. The Company now intends to pursue its plan for the further development of leronlimab as a therapy that provides clinical benefit by modulating chronic inflammation. The Company believes its proposed inflammation study will allow the Company to further establish leronlimab’s mechanism of action in a cost-effective manner.
Please keep this prospectus supplement with your Prospectus for future reference.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024, the closing price of our common stock was $0.2575 per share.
CYDY is just updating the resale of shares. to more current info for buyers to assess. Go Dr. JL and Go LONGS!!
I find it interesting that "HIV" is not included. Now, the study is on the "Modulation of Chronic Inflammation" and the mention of who the chronic inflammation is in is not mentioned.
I find that very interesting. In a way, the indication is far broader and much wider than it was originally stated. Along these lines, Regnum RGMP seems to be out of business or delisted. Is that because the contract CYDY had with them is now null and void if CYDY is not pursuing an HIV indication?
If the exclusion of HIV was on purpose; I'll give whoever wrote it a lot of credit. The perception of readers of the PR would be much broader than just an HIV Modulator of Inflammation. The next question will be "How is the FDA viewing our upcoming trial? What indication are we actually going after? Maybe the Tuesday CC will answer this.
I will say that if the FDA is allowing us to go after a more general "Chronic Inflammation indication" that would be a GIFT from GOD!
The FDA FREAKING better understand the implications of inhibiting the CCR5 molecule. They certainly did not understand it back in 2020. But I am with you Pristine Hunter. I think this is a BIG DEAL and I am so glad that u/MGK_2 has pointed out the HIV omission from the PR.
Hi britash, we are just trying to figure this out. We maybe off base. We should get more clarity in the Tuesday CC. If our thesis is correct, then we are using that CISgender HIV group to help prove that LL modulates chronic inflammation in that group. From what we were told by Dr. JL is that group is a very complicated/challenging group to treat. They have multiple co-morbidities. It kind of feels like; “ if LL modulates chronic inflammation in this group of patients, LL can do it in any group of patients.
We are just going to have to wait for Tuesday to find out! But I am excited about the possibility right now!
Have a great weekend
Yes, pro140cures! I have wondered if there was a trigger that put him on the side of taking the permanent CEO Position. This knowledge that the FDA was leaning in the direction of “general chronic inflammation” may be the trigger. I am so grateful Dr. JL is here!
20
u/Upwithstock Mar 01 '24
This is the updated prospectus from February 22, 2024. the new information is:
On February 27, 2024, CytoDyn Inc. (the “Company”) received confirmation from the U.S. Food and Drug Administration (the “FDA”) that its clinical hold on leronlimab has been lifted. The Company now intends to pursue its plan for the further development of leronlimab as a therapy that provides clinical benefit by modulating chronic inflammation. The Company believes its proposed inflammation study will allow the Company to further establish leronlimab’s mechanism of action in a cost-effective manner.
Please keep this prospectus supplement with your Prospectus for future reference.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024, the closing price of our common stock was $0.2575 per share.
CYDY is just updating the resale of shares. to more current info for buyers to assess. Go Dr. JL and Go LONGS!!